PureTech

Developing and commercializing highly differentiated medicines for devastating diseases.

Launch date

Sep 2001

Employees

Market cap

Enterprise valuation

(AUD33m) (Public information from Sep 2024)

Boston Massachusetts (HQ)

http://puretechhealth.com

https://twitter.com/puretechh https://www.linkedin.com/company/puretech-health/

Notable known LPs: JDRF

Revenues, earnings & profits over time

USD	2020	2021	2022	2023	2024	2025	2026
Revenues	8.3m	10.0m	2.1m	<1m	28.4m	35.2m	22.8m
% growth	(4 %)	20 %	(79 %)	(64 %)	3691 %	24 %	(35 %)
EBITDA	(145m)	(215m)	(203m)	(132m)	(130m)	(137m)	(140m)
% EBITDA margin	(1735 %)	(2153 %)	(9699 %)	(17641 %)	(457 %)	(389 %)	(613 %)
Profit	6.0m	(60.6m)	(50.4m)	(65.7m)	(128m)	(115m)	(147m)
% profit margin	72 %	(607 %)	(2409 %)	(8760 %)	(449 %)	(328 %)	(647 %)
EV / revenue	147.7x	72.6x	267.9x	607.3x	3.7x	2.0x	2.9x
EV / EBITDA	-8.5x	-3.4x	-2.8x	-3.4x	-0.8x	-0.5x	-0.5x
R&D budget	61.2m	81.5m	116m	73.7m	-	-	-
R&D % of revenue	734 %	817 %	5556 %	9831 %	-	-	-

Date	Investors	Amount	Round
-	Vitruvian Partners Monash Investment Holdings	N/A	-
Sep 2001	Monash University	N/A	Spinout
Jan 2015	N/A	$50.0m	Late VC
Jun 2015	N/A	N/A	IPO
Aug 2023*	US Department of Defense	$11.4m	Grant
Total Funding		AUD94.9m

Tech stackLearn more about the technologies and tools that this company uses.

By Country

United States 12

By Industry

Health 11 Music 1 Jobs Recruitment 1

By Round

SERIES A 8 SERIES B 5 ACQUISITION 1 EARLY VC 1 SERIES C 1 LATE VC 1

Karuna Therapeutics

ACQUISITION by Bristol-Myers Squibb Dec 2023

Satori Pharmaceuticals

exited

Vedanta Biosciences

Alivio Therapeutics

ACQUISITION by PureTech Jun 2021